

News Release

Suven's Income at Rs. 1466 Mn; PAT at Rs. 295 Mn for the quarter ended June 2017

HYDERABAD, INDIA (14 Aug' 2017) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June 2017. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Aug 2017 at Hyderabad.

Financial Highlights for the 1st Quarter ended June' 2017: (QoQ)

Growth in revenue	INR 1466 Mn vs. INR 1851 Mn - Down by 20.77%
Growth in PAT	INR 295 Mn vs. INR 403 Mn - Down by 26.70%
Growth in EBIDTA	INR 509 Mn vs. INR 533 Mn - Down by 4.61%

In comparison with the same period of last year, the income was higher by 6.48% and PAT was lower by 8.98%.

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of Rs 160 Mn (10.92% on revenue) for the quarter ended 30th June 2017.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;